Resolution Therapeutics Marks Milestone with First Patient Dosed in Liver Disease Trial
Resolution Therapeutics has announced a major step forward in the fight against end-stage liver disease, with the first patient now dosed and safety cleared in its phase 1/2 EMERALD study of RTX001, a pioneering engineered regenerative macrophage therapy (RMT).
A First-of-Its-Kind Therapy
RTX001 is the first engineered regenerative macrophage therapy to be evaluated in humans with advanced liver fibrosis, representing a potential breakthrough for patients with limited treatment options.
The EMERALD study is a multi-centre, single-arm, open-label clinical trial designed to assess both safety and efficacy in patients who have recovered from hepatic decompensation.
The first patient was dosed at the Royal Infirmary of Edinburgh, with trial enrolment now open across the United Kingdom and Spain. Up to 25 patients will participate in this early-stage study, which could lay the foundation for a new approach to treating one of the world’s most challenging and deadly conditions.
Addressing an Unmet Medical Need
End-stage liver disease remains a condition with high mortality and few therapeutic avenues. Most liver-related hospitalisations and deaths result from decompensated cirrhosis, where treatment options are severely limited.
Liver transplantation remains effective but is constrained by donor shortages, high costs, and its suitability for only a fraction of patients.
Resolution Therapeutics aims to change this landscape. RTX001 has the potential not only to extend patients’ lives but also to improve their quality of life, offering hope where none currently exists.
Expert Voices on the Breakthrough
The Chief Executive Officer of Resolution Therapeutics hailed the dosing of the first patient as a significant milestone in advancing RTX001 as a potential first-in-class treatment option. The company expects to share its first clinical readouts from the EMERALD study in 2026, marking an eagerly anticipated moment in liver disease research.
The Chief Investigator of the trial emphasised the urgency of developing new therapies, noting that there are no licensed treatments that stabilise or reverse disease at this late stage. Furthermore, they described RTX001 as a crucial opportunity to address an area of medicine that has long been overlooked.
An Advisory Board Member at Resolution Therapeutics highlighted the therapy’s potential, stating that RTX001 may give patients suffering from decompensated cirrhosis the ability to live longer and potentially improve quality of life
Adding to this momentum, the Director of Communications & Policy at the British Liver Trust expressed strong encouragement, describing the study as a promising advance and sharing excitement about future data from the phase 1/2 EMERALD trial.
Looking Ahead
With its innovative regenerative macrophage therapy, Resolution Therapeutics is taking bold steps toward reshaping the treatment landscape for end-stage liver disease. The dosing of the first patient marks not only a milestone for the company but also a moment of hope for thousands of patients worldwide.
As the EMERALD study progresses and further data emerges, the medical community and patient advocates alike will be watching closely. If successful, RTX001 could represent a new era in liver disease treatment – combining innovation, science, and compassion to tackle a condition with historically few options.
News Credits: Resolution Therapeutics doses first patient in EMERALD study of RTX001
Things you may also like: